Zacks Investment Research lowered shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) from a buy rating to a hold rating in a report released on Thursday morning.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Caladrius Biosciences in a research report on Friday, November 10th. ValuEngine raised Caladrius Biosciences from a strong sell rating to a sell rating in a research report on Friday, September 1st.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 96.80% and a negative net margin of 84.10%. analysts expect that Caladrius Biosciences will post -2.33 EPS for the current year.
Hedge funds have recently bought and sold shares of the business. KCG Holdings Inc. grew its position in Caladrius Biosciences by 74.6% during the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 15,501 shares during the period. Renaissance Technologies LLC grew its position in Caladrius Biosciences by 34.3% during the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after acquiring an additional 24,900 shares during the period. Finally, Vanguard Group Inc. grew its position in Caladrius Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after acquiring an additional 4,163 shares during the period. 6.36% of the stock is owned by hedge funds and other institutional investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.